Sleep
Behavioral · Evidence and recent research
Notify me when meaningful evidence changes.
Where things stand
Sleep supports mental and physical health, alertness and day-to-day function. Persistent poor sleep can also signal a treatable condition such as sleep apnea, rather than simply normal ageing. The useful distinction is between improving sleep health and claiming that a particular sleep duration or product will extend lifespan. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia”. Its implications have not yet been summarized in a source-checked review. Read update ↗
AI-written overview · not expert-reviewed · Background sources checked Sep 23, 2026 · Recent updates cover the last 30 days of this collection. A new report does not automatically change the evidence assessment.
Background and coverage
- Regulatory status
- Not applicable
- Availability
- Widely available
- Category
- Behavioral
- Human results verified here
- 0
Evidence collection is needs review. 0 approved assessments; 57 assessments awaiting review; 0 published studies with verified results. Safety: not assessed.
Recorded evidence activity (experimental)
A numeric breakdown will be available after baseline review. Safety is not yet assessed.
What changed
Evidence events affecting this intervention
Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia
Trial registry update: ENROLLING_BY_INVITATION. No results reported in the supplied registry record.
RCT of NightWare wearable device for PTSD-related nightmares and cardiovascular outcomes in veterans
This randomized controlled trial examined whether NightWare, a prescription wrist-wearable device, improves sleep and cardiovascular health in veterans with PTSD-related nightmares. The study aimed to assess the device's effectiveness in these outcomes, though the abstract does not report results, sample size, or effect estimates.
RCT evaluates urolithin A and fisetin on sleep quality and aging biomarkers in middle-aged and older adults
This randomized controlled trial compared four groups—placebo, 500 mg urolithin A, 500 mg fisetin, and a 300 mg urolithin A + 200 mg fisetin combination—over 12 weeks in middle-aged and older adults. Participants took daily capsules and underwent assessments at baseline, week 4, and week 12, including sleep quality measures (PSQI, actigraphy, polysomnography), aging biomarkers (DNA methylation, inflammatory cytokines), and gut microbiome analysis. The abstract describes the study design and planned assessments but does not report any results or findings.
Assessment history
The 25 most recent recorded changes, including corrections and backfill
Human studies with verified results
No published human results verified in this collection yet
Animal and mechanistic evidence
No preclinical studies tracked yet
Clinical trials
Claims
Testable statements and where the evidence stands